Shree Ganesha remedies #SGRL
MKT CAP - 450 CR
PRICE -360( 4/6/23)
Promoter 63% - 69% (strong idea of generation)
P/E- 26 fairly valued
ROCE - 25%
ROE- 22%
PEG - 0.90
ALMOST DEBT FREE.
Betting on promoter 80% & 20% with good OPM % .🧵
1/n SGRL is engaged in the business of Pharma Intermediate.
In July 2021, SGRL successfully commenced the commercial production of a newly developed Cyclo-Propyl derivative. This is used in drugs like Naltrexone google.com/url?sa=t&sourc…. & Buprenorphine ncbi.nlm.nih.gov/books/NBK45912…
2/n Both drugs are used as medication used to manage alcohol and opioid use disorder by reducing cravings and easing the pain. This Cyclo-Propyl derivative is mainly being imported into India.
3/n SGRL succesfuly commision new Plant in 21 at Ankleshwar,with install production capacity of 54 kL for its existing products, funded entirely thru internal accruals,focused on value added products, any threats to margins due to increase supply & raw material cost inflatiIon
4/n Exports accounted for ~80% of FY20 sales.SGRL exports Drug Intermediates & Pharmaceuticals to more than 30 countries & is focused on growing export
SGRL acquired Ashok Pharma Chem, an API mfg & leader in Di Nitro Ortho Tolumide Bp Vet. SGRL is part of Ganesh Grp Of Ind.
5/n Wide Product Range
Company mfg products relating to antipsychotic,antiseptic, deprotonation reactions, hyperlipidemia, alzheimers & anti-viral.
Experienced Promoters
Promoters have experience of about 2 decades in pharmaceutical industry.
Most of note ready on screener
6/n SGRL has extensive portfolio of 39 products of drug intermediate & 18 speciality chemicals products, with an operational areaof over 1,90,000 sq foot , we also have technology advance modern pilot plant backed by strong research and analytics facilities
7/n SGRL is spread over 15 country,covering a good number of customers &strategic mkt alliance
Our mfg focus
✨API intermediate for human & veterinary life sciences
✨ Speciality chemicals for aroma & Pharma industry
✨Fine chemicals for agro & polymer industry
8/n ✨ 4 products with 50% or more mkt share
✨Clientele spead over 15 country
Strong export performance
✨ 3.4 % avg annual R& D SPEND tradeindia.com/products/dinit…
9/n
10/n Sales with stable OPM good margin above 20% means some quality they are selling
11/n
12/n Fantastic result when Pharma sector is headwind with China dumping their inventory ,1
12/n Fantastic result when Pharma sector is headwind with China dumping their inventory ,1
13/n Lots of Greenfield expansion is there , prmoters is very smart and ethical, believing in long-term relationship with profit, this more on betting on promoter with good margin in biz , own conviction of ground research may be biased.
14/n Concern
✨Inventory days
✨China dumping
✨Any changes in relationship with company
✨In Future pricing power
15/n Source
Screener
AR.
Not sebi registered
Pls consult your financial advisor.
Disc invested no reco .
This is my first company with own conviction, scuttlebutt & less tracking 🙏🧵
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Hello every one recently Guna sir make his 4 hour long twitter space 🚀, i had made some take away for better for everyone pls like & RT , tell what is your favourite line conducted by Aditya ji @Aditya_joshi12 & @soverennofficial
1/n PUNYA
P- Promoters stand for vision
U- under research company
N- New business
Y- young mkt cap
A - Affordable price/ valuation
✨Betting on right promoter is almost 80% job done
✨Making money is by product
✨ Paisa wahin jahan koi nahin
✨ Less than < 100 CR mkt cap.
2/n Chota admi ke sath kaam Karo
✨ Pharma mein company mili negative working capital 😍.
✨ Pondicherry chemicals based company China ko supply strange
✨micro cap relationship is more imp.
✨bet on honest with smart promoter, itna honest bhi mat bano ki 1 month plant bandh
One of the only listed Medical College with hospital in listed Space in India , valuation is favorable still ,with little sense of humour , let's start✨ 🙏🧵 #kovai
1/n Greatest event that has taken place In the history of kovai medical College , inauguration of new medical College in coimbatore, with an intake of 150 MBBS students with affiliation of Tamilnadu DR.MGR Medical University- AR20
AT 23 ALMOST 4 BATCH COMPLETED.
2/n DNB course offered
✨Cardiology
✨General surgery
✨Critical care medicine
✨Internal medicine
✨Orthopedic
✨Paediatric
✨Urology
👉ICU COURSES
👉Fellow ship program
It's only intensive Care unit in South India,which has recognised by Fellow ship Program.
✨Frm 2003-13,it raised production to 7.1 bcpa,
expanded to overseas mkt & added marque client portfolio
2/n ✨2015-2018;
Was the period of big chill - falling oil threw public finance of commodity driven African market into tizzy and NCL growth froze ,margin collapse, demonetization / GST prevent India switch
#RPG#rpglife life science business analysis,
It's was my diwali pick trying make two cent to add some value
A turnaround company with margins expansion & get rid off from DPCO specially your monopoly product ✨🧵
1/n 👉Leader in immunosuppressant segment
👉50+ year rich legacy, integrated operation with capabilities of both development & mfg in API & formulation,
👉company operating in domestic & international mkts in branded formulation,
👉global generic, API🧬💊
2/n 👉6 text book brand are trusted by doctor and patient
👉3 mfg units
👉1100+ permanent employee
👉50+ countries presence,
👉Enduring relationship with leading generic players of World 🌍
Second wave of COVID 19 impacted lives ,bussiness across the board.
We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.
2/n Even the world experienced chaos and disruption, we delivered our highest growth .
FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%
3/n Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago. #betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.
Gufic bio science stock analysis
( RT if beneficial)
A Thread 🧵🧵👇
1/n Company analysis
Mkt cap 2280( 18/03/2022)
CMP 235
P/E 25
ROCE 29%
ROE -29%
PROMOTER HOLDING 65% TO 75%
DEBT TO EQUITY ALMOST NIL
2/n gufic is engaged in r&d, mfg, mkt,distribution & sale of pharma & allied products,3rd fastest growing among the 100 pharma in india,largest mfg of lyophilized injection in india & fully automated,therapy areas like antibiotic,antifungal,cardiac, infertilty,antiviral, ppi.